Epidemiological Study in FRONtoTemporal Dementia (EFRONT)

CENTOGENE

Status

Active, not recruiting

Conditions

Frontotemporal Dementia

Treatments

Diagnostic Test: Genetic Screening

Study type

Observational

Funder types

Industry

Identifiers

NCT05075187

EFRONT 05-2021

Details and patient eligibility

About

An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.

Full description

Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal and temporal lobes. This leads to abnormalities in behaviour, personality, and language comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity, difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial aggregation). For this study, blood samples were collected from clinically diagnosed or suspected FTD patients and were analysed for a broad range of pathogenic variants in genes associated with FTD. The scientific insights acquired from this study will help identify novel therapeutic targets and develop/ investigate potential disease-modifying drugs.

Enrollment

4,500 estimated patients

Sex

All

Ages

25 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian
The participant is aged between 25 to 85 years
The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD